Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Drug Resist Updat ; 75: 101087, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38678745

ABSTRACT

In recent years, new evidence has shown that the SOS response plays an important role in the response to antimicrobials, with involvement in the generation of clinical resistance. Here we evaluate the impact of heterogeneous expression of the SOS response in clinical isolates of Escherichia coli on response to the fluoroquinolone, ciprofloxacin. In silico analysis of whole genome sequencing data showed remarkable sequence conservation of the SOS response regulators, RecA and LexA. Despite the genetic homogeneity, our results revealed a marked differential heterogeneity in SOS response activation, both at population and single-cell level, among clinical isolates of E. coli in the presence of subinhibitory concentrations of ciprofloxacin. Four main stages of SOS response activation were identified and correlated with cell filamentation. Interestingly, there was a correlation between clinical isolates with higher expression of the SOS response and further progression to resistance. This heterogeneity in response to DNA damage repair (mediated by the SOS response) and induced by antimicrobial agents could be a new factor with implications for bacterial evolution and survival contributing to the generation of antimicrobial resistance.


Subject(s)
Anti-Bacterial Agents , Ciprofloxacin , Escherichia coli Proteins , Escherichia coli , Microbial Sensitivity Tests , Rec A Recombinases , SOS Response, Genetics , SOS Response, Genetics/drug effects , Escherichia coli/drug effects , Escherichia coli/genetics , Ciprofloxacin/pharmacology , Humans , Escherichia coli Proteins/genetics , Escherichia coli Proteins/metabolism , Anti-Bacterial Agents/pharmacology , Rec A Recombinases/genetics , Rec A Recombinases/metabolism , Drug Resistance, Bacterial/genetics , Serine Endopeptidases/genetics , Serine Endopeptidases/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , DNA Damage/drug effects , Whole Genome Sequencing , Escherichia coli Infections/microbiology , Escherichia coli Infections/drug therapy , Gene Expression Regulation, Bacterial/drug effects , Adaptation, Physiological , DNA Repair/drug effects , DNA-Binding Proteins
2.
Mol Cancer ; 23(1): 37, 2024 02 19.
Article in English | MEDLINE | ID: mdl-38374062

ABSTRACT

Soft tissue sarcomas (STS) are diverse mesenchymal tumors with few therapeutic options in advanced stages. Trabectedin has global approval for treating STS patients resistant to anthracycline-based regimens. Recent pre-clinical data suggest that trabectedin's antitumor activity extends beyond tumor cells to influencing the tumor microenvironment (TME), especially affecting tumor-associated macrophages and their pro-tumoral functions. We present the phase I/II results evaluating a combination of metronomic trabectedin and low-dose cyclophosphamide on the TME in patients with advanced sarcomas. 50 patients participated: 20 in phase I and 30 in phase II. Changes in the TME were assessed in 28 patients using sequential tumor samples at baseline and day two of the cycle. Treatment notably decreased CD68 + CD163 + macrophages in biopsies from tumor lesions compared to pre-treatment samples in 9 of the 28 patients after 4 weeks. Baseline CD8 + T cell presence increased in 11 of these patients. In summary, up to 57% of patients exhibited a positive immunological response marked by reduced M2 macrophages or increased CD8 + T cells post-treatment. This positive shift in the TME correlated with improved clinical benefit and progression-free survival. This study offers the first prospective evidence of trabectedin's immunological effect in advanced STS patients, highlighting a relationship between TME modulation and patient outcomes.This study was registered with ClinicalTrial.gov, number NCT02406781.


Subject(s)
Antineoplastic Agents, Alkylating , Sarcoma , Humans , Trabectedin/therapeutic use , Prospective Studies , Antineoplastic Agents, Alkylating/therapeutic use , Sarcoma/drug therapy , Sarcoma/pathology , Cyclophosphamide/therapeutic use , Dioxoles , Tumor Microenvironment
3.
Environ Sci Pollut Res Int ; 31(31): 43896-43902, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38913264

ABSTRACT

Hospital sewage is an ecosystem that facilitates the transfer of antibiotic and heavy metal resistance genes and the interaction of human and environmental bacteria. In this environment, we have detected the presence of 7 KPC-2 and BEL-1 co-producing E. coli isolates of two different clones over a 10-month period in the same hospital. All isolates carried blaKPC-2 and the operon mer on the same IncP plasmid of similar size and an IncN plasmid of different size each clone carrying blaBEL-1. Both IncN-blaBEL-1 plasmids shared a 77 kb region containing blaBEL-1 alongside with fosE, bla OXA-10 and aac(6')-1b genes in a class 3 integron within a Tn3 transposon. The major IncN plasmid contained in addition a region homolog to P1-like bacteriophage RCS47, including the lytic RepL and lysogenic proteins, but other phage regions were incomplete. The characters such as the temporal persistence in sewage, the absence of colonized patients in the hospital or in the region, the presence of a p1 phage-plasmid fusion and the infrequent class 3 integron as genetic platform would indicate that BEL-1-producing isolates could have been generated in situ by adaptation to human sewage. Part of the microbiota in these discharges could be explained by the interactions of sewage ecosystems and not derive directly from the hospital.


Subject(s)
Escherichia coli , Hospitals , Sewage , Wastewater , beta-Lactamases , Escherichia coli/genetics , Humans , Sewage/microbiology , Wastewater/microbiology , beta-Lactamases/genetics , Plasmids/genetics , Integrons
SELECTION OF CITATIONS
SEARCH DETAIL